GAMMA Investing’s Immunovant IMVT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$28.8K Buy
748
+44
+6% +$1.34K ﹤0.01% 2641
2026
Q1
$17.5K Buy
704
+192
+38% +$4.97K ﹤0.01% 2783
2025
Q4
$13K Buy
512
+162
+46% +$3.61K ﹤0.01% 2850
2025
Q3
$5.64K Buy
350
+48
+16% +$777 ﹤0.01% 3130
2025
Q2
$4.83K Sell
302
-12
-4% -$181 ﹤0.01% 3136
2025
Q1
$5.37K Buy
314
+177
+129% +$3.7K ﹤0.01% 3059
2024
Q4
$3.39K Buy
137
+45
+49% +$1.28K ﹤0.01% 3056
2024
Q3
$2.62K Buy
92
+14
+18% +$413 ﹤0.01% 2980
2024
Q2
$2.06K Sell
78
-32
-29% -$910 ﹤0.01% 2876
2024
Q1
$3.55K Buy
110
+31
+39% +$1.13K ﹤0.01% 2542
2023
Q4
$2.88K Buy
+79
New +$2.91K ﹤0.01% 2461

Other funds holding IMVT

GAMMA Investing's IMVT Position: Q2 2026 in Review

GAMMA Investing increased its Immunovant (IMVT) stake by 6.3% in Q2 2026, buying an estimated $1.34K and bringing the position to 748 shares worth $28.8K. The position accounts for ﹤0.01% of the portfolio, ranked #2641.

GAMMA Investing first reported a position in IMVT in Q4 2023 and has held it in 11 quarters since. 9 funds tracked by Wall St. Rank hold IMVT as of Q2 2026.

  • GAMMA Investing held 748 shares of Immunovant worth $28.8K as of Q2 2026.
  • GAMMA Investing bought 44 Immunovant shares in Q2 2026, an estimated $1.34K.
  • Immunovant made up ﹤0.01% of GAMMA Investing's portfolio in Q2 2026, its #2641 holding.
  • GAMMA Investing first reported a position in Immunovant in Q4 2023 and has held it in 11 quarters since.
  • 9 funds tracked by Wall St. Rank held Immunovant as of Q2 2026.

Based on GAMMA Investing's 13F filing for Q2 2026, filed 7 Jul 2026.